The gastrointestinal drugs market is poised to expand from $59.3 billion in 2023 to $97.8 billion by
The Gastrointestinal Drugs Market encompasses the sector dedicated to developing, manufacturing, and distributing medications aimed at treating disorders of the digestive system. This includes a wide range of pharmaceuticals such as antacids, laxatives, antiemetics, and proton pump inhibitors, addressing conditions like acid reflux, irritable bowel syndrome, and Crohn\'s disease. The market is driven by rising prevalence of gastrointestinal diseases, increasing geriatric population, and advancements in drug delivery systems, offering significant growth opportunities in therapeutic innovation and patient care.